Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa

Jay Jiyong Kwak¹, Hae Rang Kim², and Suk Ho Byeon¹

¹Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul; ²Department of Ophthalmology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.

INTRODUCTION

Inherited retinal diseases (IRDs) refer to a large group of clinically and genetically heterogeneous disorders characterized by photoreceptor degeneration or dysfunction.¹ RPE65-mediated retinal dystrophy is one type of IRD in which mutation of the RPE65 gene leads to inhibition of RPE65 all-trans-retinyl isomerase activity, thereby leading to decreased levels of rhodopsin and eventually to photoreceptor and retinal pigment epithelium (RPE) cell loss.²,³ Early symptoms include night blindness and nystagmus, with progressive deterioration in visual acuity (VA) and visual field (VF). Disease onset ranges from congenital to late adulthood.³,⁴ Gene therapy is a new treatment option for IRD patients. Adeno-associated viral (AAV) vectors represent the most promising approach for IRDs as they lack pathogenicity, exhibit minimal immunogenicity, and mediate sustained levels of transgenic expression.⁵ As retinal cell degeneration is irreversible, vector efficacy depends on the number of viable cells available, as well as the ability to reach target cells effectively.⁶ Voretigene neparvovec-rzyl (VN) is the first in vivo viral gene therapy agent to be approved. At 3 months after subretinal injection of VN in the left eye, VA, VF, and FST showed sustained improvement. She did not exhibit any signs of adverse effects from the treatment. Gene therapy for RP proved to be an effective and safe treatment in an advanced case of RPE65-associated early onset RP.

Key Words: Retinitis pigmentosa, leber congenital amaurosis, hereditary eye disease, gene therapy

CASE REPORT

A 30-year-old female patient visited our clinic for progressive vision loss. She first presented to us at age 2 with low vision. There was no known ocular disease in her family except for her younger brother who complained of low vision. The patient underwent vitrectomy for macular holes in her right eye at age 27. Preoperative best-corrected visual acuities (BCVAs) were 20/500 in the right eye and 20/200 in the left eye. Dilated fundus examination revealed salt-and-pepper mottling (Fig. 1A-1 and B-1). Her bilateral VF was severely constricted (Fig. 1C-1 and D-1). She met the diagnostic criteria for congenital stationary night blindness [CSNB].

There was no known ocular disease in her family except for her younger brother who complained of low vision. The patient underwent vitrectomy for macular holes in her right eye at age 27. Preoperative best-corrected visual acuities (BCVAs) were 20/500 in the right eye and 20/200 in the left eye. Dilated fundus examination revealed salt-and-pepper mottling (Fig. 1A-1 and B-1). Her bilateral VF was severely constricted (Fig. 1C-1 and D-1).
2A-1, A-4, B-1, and B-4). Spectral-domain optical coherence tomography (OCT) revealed outer retinal and RPE atrophy (Fig. 1A-4 and B-4). Preoperative full-field stimulus threshold test (FST) for her left eye showed -3.13 dB for white signals. Genetic testing identified c.1543C>T and c.1067dupA biallelic compound heterozygote mutations in the RPE65 gene.6,8

Three days before injection, the patient was given oral corticosteroids (40 mg/day) in order to counteract any potential immunization effects of the viral vector and transgene.10 The active substance and solvent of VN were stored at a temperature below -65°C and thawed at the time of use. The preparation of VN took place aseptically. Under general anesthesia, 25-gauge pars planar vitrectomy was performed on the left eye. After a core vitrectomy and induction of posterior vitreous detachment, we injected VN subretinally, superonasal and inferonasal to the fovea, with a 41-gauge cannula, resulting in two blebs (Fig. 3).

As early as 1 month after treatment, the patient noted subjective improvement in central vision of her left eye though BCVA (20/400) did not show improvement. BCVA in her left eye improved to 20/100 at 3 months. For her right eye, BCVA at 1 and 3 months remained at 20/500. Humphrey and Goldmann VF tests revealed improved central VF at 1 and 3 months in her left eye (Fig. 2A-2, A-3, A-5, and A-6), but not in the right eye (Fig. 2B-2, B-3, B-5, and B-6). Based on results from worsening Humphrey VF and stationary BCVA in her right eye, we concluded that that Goldmann VF at 3 months for her right
eye was not taken accurately. VF index (VFI) in the left eye increased from 9% preoperatively to 10% and 11% at 1 and 3 months, respectively. VFI in the right eye decreased from 10% preoperatively to 8% and 5% at 1 and 3 months. Though wide fundus photographs of the left eye did not show noticeable changes, compared to her right eye, during the 3 months of follow up (Fig. 1A-2, A-3, B-2, and B-3), her OCT scans of the left eye showed more distinct photoreceptor inner segment/outer

Fig. 2. Humphrey visual field (VF) tests of the left eye before gene therapy (A-1), 1 month after treatment (A-2), and 3 months after treatment (A-3). Goldmann VF tests of the left eye before gene therapy (A-4), 1 month after treatment (A-5), and 3 months after treatment (A-6). Both tests show that the patient’s central VF improved with time after treatment. Humphrey VF tests of the right eye at baseline (B-1), 1 month (B-2), and 3 months (B-3). Goldmann VF tests of the right eye at baseline (B-4), 1 month (B-5), and 3 months (B-6).
segment junction line up to 3 months, compared to her right eye (Fig. 1A-5, A-6, B-5, and B-6). FST results for white signals improved to -23.4 and -29.8 dB at 1 and 3 months, respectively. The patient did not show any signs of adverse effects, including, intraocular inflammation, macular hole, and retinal detachment (Fig. 1A-2 and A-3).

**DISCUSSION**

VN is the first and so-far the only gene therapy for IRDs. Unlike other treatments, such as nutritional supplement for macular degeneration, VN is a durable therapy tantamount to cure of *RPE65*-mediated early onset RP [Leber congenital amaurosis (LCA)]. The longstanding efficacy of VN is derived from the fact that the therapeutic gene is incorporated into the cell nucleus as a stable extragenic episome, designed to be expressed constitutively.11

*RPE65*-mediated early onset retinitis pigmentosa (RP) (LCA) is known to cause night blindness, substantial loss of vision, and progressive VF loss during the first three decades of life.6,12 Patients over age 30 suffer from near-total blindness.13,14 At age 9, this patient showed severe rod-cone dysfunction on electroretinography with peripheral retinal pigmentary change. By age 15, her peripheral VF was substantially constricted. At age 30, BCVA was 20/200, and VF was severely constricted in her left eye, indicating advanced stage. The indication for VN is that the patient must have viable retinal cells, with retinal thickness at the posterior pole greater than 100 μm. Despite being at an advanced stage, the patient was considered appropriate to undergo VN because the outer retina was preserved and retinal thickness at the posterior pole was 141 μm. We decided to treat only her left eye as her right eye had been treated with macular hole operation, which would have drastically
reduced the efficacy of VN. After treatment, the patient showed improvement in VF and FST at 1 month, which continued to improve at 3 months. Drastic improvement in BCVA may have been limited due to the fact that BCVA is a measure of foveal, cone-mediated function and that BCVA was not the primary target of the intervention in this rod-mediated disease. Moreover, our patient already showed signs of advanced disease. Previous reports have indicated that young children with better VA and a relatively preserved outer retinal layer show the greatest improvement, compared to adults. The patient in this study experienced visual improvement that cannot be simply measured by BCVA or VF tests. She claimed that she is now able to see objects clearly and to walk independently at night.

One limitation of AAV vectors include their limited packaging capacity. Treatment of IRDs caused by mutations in genes whose coding sequence exceeds 5 kb require dual AAV vectors or other vectors with larger packing capacity. In addition, due to the rarity of the disease, large-scale, long-term follow-up results are limited. However, recent reports have shown that VN improved visual function up to 3 to 5 years.

We report the post-treatment outcomes of VN in RPE65-mediated early onset RP. With careful patient selection, VN is an effective therapy that leads to improvement in visual and anatomical outcomes in RPE65-mediated early onset RP (LCA) within months. Continued long-term observation is planned.

ACKNOWLEDGEMENTS

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT) (No. 2019R1A2C2086729).

AUTHOR CONTRIBUTIONS

Conceptualization: Jay Jiyong Kwak and Suk Ho Byeon. Data curation: all authors. Formal analysis: all authors. Funding acquisition: Suk Ho Byeon. Investigation: Jay Jiyong Kwak and Suk Ho Byeon. Methodology: Suk Ho Byeon. Project administration: Suk Ho Byeon. Resources: Suk Ho Byeon. Software: all authors. Supervision: Suk Ho Byeon. Validation: Suk Ho Byeon. Writing—original draft: Jay Jiyong Kwak and Suk Ho Byeon. Writing—review & editing: Jay Jiyong Kwak and Suk Ho Byeon. Approval of final manuscript: all authors.

ORCID iDs

Jay Jiyong Kwak https://orcid.org/0000-0002-7738-9136
Hae Rang Kim https://orcid.org/0000-0003-3226-6148
Suk Ho Byeon https://orcid.org/0000-0001-8101-0830

REFERENCES

1. Georgiou M, Fujinami K, Michaelides M. Inherited retinal diseases: therapeutics, clinical trials and end points—A review. Clin Exp Ophthalmol 2021;49:270-88.
2. Travis GH, Golczak M, Moise AR, Palczewski K. Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. Annu Rev Pharmacol Toxicol 2007;47:469-512.
3. Kang C, Scott LJ. Voretigene neparvovec: a review in RPE65 mutation-associated inherited retinal dystrophy. Mol Diagn Ther 2020;24:487-95.
4. Astuti GD, Bertelsen M, Preising MN, Ajmal M, Lorenz B, Faradz SM, et al. Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark. Eur J Hum Genet 2016;24:1071-9.
5. Zicardi L, Cordeddu V, Gaddini L, Matteucci A, Parravano M, Mancioli-Albedi F, et al. Gene therapy in retinal dystrophies. Int J Mol Sci 2019;20:5722.
6. Lopez-Rodriguez R, Lantero E, Blanco-Kelly F, Avila-Fernandez A, Martin Merida I, Del Pozo-Valero M, et al. RPE65-related retinal dystrophy: mutational and phenotypic spectrum in 45 affected patients. Exp Eye Res 2021;212:108761.
7. Hull S, Holder GE, Robson AG, Mukherjee R, Michaelides M, Webster AR, et al. Preserved visual function in retinal dystrophy due to hypomorph RPE65 mutations. Br J Ophthalmol 2016;100:1499-505.
8. Katagiri S, Hosono K, Hayashi T, Kurata K, Mizobuchi K, Matsuura T, et al. Early onset flecked retinal dystrophy associated with new compound heterozygous RPE65 variants. Mol Vis 2018;24:286-96.
9. Kondo H, Qin M, Mizota A, Kondo M, Hayashi H, Hayashi K, et al. A homozygosity-based search for mutations in patients with autosomal recessive retinitis pigmentosa, using microsatellite markers. Invest Ophthalmol Vis Sci 2004;45:4433-9.
10. Maguire AM, Bennett J, Alaman EM, Leroy BP, Alaman TS. Clinical perspective: treating RPE65-associated retinal dystrophy. Mol Ther 2021;29:42-63.
11. Giulli TA, Hussain RM, Berrocal AM, Nagiel A. Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development. Expert Opin Biol Ther 2020;20:565-78.
12. Gu SM, Thompson DA, Srikumari CR, Lorenz B, Finchuk U, Nicoletti A, et al. Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat Genet 1997;17:194-7.
13. Chung DC, Bertelsen M, Lorenz B, Pennesi ME, Leroy BP, Hamel CP, et al. The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene. Am J Ophthalmol 2019;189:58-70.
14. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017;390:849-60.
15. Maguire AM, High KA, Auricchio A, Wright JP, Pierce EA, Testa F, et al. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009;374:1597-605.
16. Welleber RG, Pennesi ME, Wilson DJ, Kaushal S, Erker LR, Jensen L, et al. Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmoiology 2016;123:1606-20.
17. Maguire AM, Russell S, Chung DC, Yu ZF, Tillman A, Drack AV, et al. Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years. Ophthalmology 2021;128:1460-8.
18. Bennett J, Russell SR, High KA, Drack AV, Yu ZF, Chung DC, et al. Five-year post-injection results of the phase 3 trial of voretigene neparvovec-rzyl in biallelic RPE65 mutation-associated inherited retinal disease. Invest Ophthalmol Vis Sci 2021;62:3540.